Clinical Trials | December 05, 2022
Jemperli RUBY phase III trial met its primary endpoint
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The plan is to advance innovative therapies to drug-resistant cancers
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
The campaign aims to promote women’s health and wellness and urge them to visit the hospital for key medical check-ups
Subscribe To Our Newsletter & Stay Updated
